Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study-Reference-Cited by-同舟云学术

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study

Published:2013-06 Issue:6 Volume:24 Page:1560-1567
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Schultheis B.,Folprecht G.,Kuhlmann J.,Ehrenberg R.,Hacker U.T.,Köhne C.H.,Kornacker M.,Boix O.,Lettieri J.,Krauss J.,Fischer R.,Hamann S.,Strumberg D.,Mross K.B.

Funder

Bayer Pharma AG

Bayer HealthCare Pharmaceuticals

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/6/1560/435960/mdt056.pdf

Reference37 articles.

1. Colorectal Cancer Fact Sheet 2008;Globocan,2010

2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon Cancer. Version 3.2012;National Comprehensive Cancer Network,2012

3. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment;Van Cutsem;Ann Oncol,2010

4. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741;Sanoff;J Clin Oncol,2008

5. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study;Cancer Chemotherapy and Pharmacology;2024-07-10

2. Natural Stilbenes: Their Role in Colorectal Cancer Prevention, DNA Methylation, and Therapy;Nutrition and Cancer;2024-07

3. Sidedness and addition of chemotherapy associated with treatment outcomes of regorafenib for metastatic colorectal cancer: a population-wide cohort study;ESMO Gastrointestinal Oncology;2024-06

4. Allosteric SHP2 inhibition enhances regorafenib's effectiveness in colorectal cancer treatment;Biochemical and Biophysical Research Communications;2024-05

5. Artificial intelligence systems for the design of magic shotgun drugs;Artificial Intelligence in the Life Sciences;2023-12